Article: Penetration of ((14)C)-Efinaconazole Topical Solution, 10%, Does Not Appear to be Influenced by Nail Polish

Onychomycosis is a common nail disorder with significant medical impacts and aesthetic consequences. Patients seek treatment for several reasons, including the unsightliness of the nail(s). Even with successful management, it takes months for the diseased nail to appear cosmetically normal. Patients commonly apply nail polish to mask the appearance of the dystrophic nail, though it is contraindicated with the currently available topical lacquers for onychomycosis. The authors' nonclinical study using a cadaver nail model showed that penetration of efinaconazole topical solution, 10%, a new antifungal being developed for the treatment of mild-to-moderate toenail onychomycosis, was not influenced by application of nail polish. Polishes showed an increase in surface tackiness with repeated efinaconazole topical solution, 10% application. The medical and aesthetic significance of the authors' findings have yet to be assessed clinically.

Citing Articles

Concealing Meets Healing in the Treatment of Toenail Onychomycosis: A Review of Concurrent Nail Polish Use with Topical Efinaconazole 10% Solution.

Pandit B, Elewski B, Vlahovic T J Clin Aesthet Dermatol. 2024; 17(9):38-42.

PMID: 39263266 PMC: 11386970.

Treatment Options for Onychomycosis: Efficacy, Side Effects, Adherence, Financial Considerations, and Ethics.

Yousefian F, Smythe C, Han H, Elewski B, Nestor M J Clin Aesthet Dermatol. 2024; 17(3):24-33.

PMID: 38495549 PMC: 10941855.

On the Basis of Sex: Impact and Treatment of Toenail Onychomycosis in Female Patients.

Lipner S, Falotico J, Konda A J Clin Aesthet Dermatol. 2023; 16(10):52-57.

PMID: 37915332 PMC: 10617899.

Updated Perspectives on the Diagnosis and Management of Onychomycosis.

Falotico J, Lipner S Clin Cosmet Investig Dermatol. 2022; 15:1933-1957.

PMID: 36133401 PMC: 9484770. DOI: 10.2147/CCID.S362635.

Ciclopirox Hydroxypropyl Chitosan (CPX-HPCH) Nail Lacquer and Breathable Cosmetic Nail Polish: In Vitro Evaluation of Drug Transungual Permeation Following the Combined Application.

Monti D, Tampucci S, Paganini V, Burgalassi S, Chetoni P, Galvan J Life (Basel). 2022; 12(6).

PMID: 35743832 PMC: 9225083. DOI: 10.3390/life12060801.

References

1.

Gupta A, Jain H, Lynde C, Macdonald P, Cooper E, Summerbell R . Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter canadian survey of 15,000 patients. J Am Acad Dermatol. 2000; 43(2 Pt 1):244-8. DOI: 10.1067/mjd.2000.104794. View

2.

Szepietowski J, Reich A, Pacan P, Garlowska E, Baran E . Evaluation of quality of life in patients with toenail onychomycosis by Polish version of an international onychomycosis-specific questionnaire. J Eur Acad Dermatol Venereol. 2007; 21(4):491-6. DOI: 10.1111/j.1468-3083.2006.02004.x. View

3.

Seebacher C, Brasch J, Abeck D, Cornely O, Effendy I, Ginter-Hanselmayer G . Onychomycosis. Mycoses. 2007; 50(4):321-7. DOI: 10.1111/j.1439-0507.2006.01351.x. View

4.

Szepietowski J, Reich A, Garlowska E, Kulig M, Baran E . Factors influencing coexistence of toenail onychomycosis with tinea pedis and other dermatomycoses: a survey of 2761 patients. Arch Dermatol. 2006; 142(10):1279-84. DOI: 10.1001/archderm.142.10.1279. View

5.

Szepietowski J, Reich A . Stigmatisation in onychomycosis patients: a population-based study. Mycoses. 2008; 52(4):343-9. DOI: 10.1111/j.1439-0507.2008.01618.x. View

6.

Elewski B . The effect of toenail onychomycosis on patient quality of life. Int J Dermatol. 1997; 36(10):754-6. DOI: 10.1046/j.1365-4362.1997.00163.x. View

7.

Roberts D . Onychomycosis: current treatment and future challenges. Br J Dermatol. 2000; 141 Suppl 56:1-4. DOI: 10.1046/j.1365-2133.1999.00007.x. View

8.

Elewski B, Rich P, Pollak R, Pariser D, Watanabe S, Senda H . Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies. J Am Acad Dermatol. 2012; 68(4):600-608. DOI: 10.1016/j.jaad.2012.10.013. View

9.

Drake L . Quality of life issues for patients with fungal nail infections. AIDS Patient Care. 1995; 9 Suppl 1:S15-7. View

10.

CRISSEY J . Common dermatophyte infections. A simple diagnostic test and current management. Postgrad Med. 1998; 103(2):191-2, 197-200, 205. DOI: 10.3810/pgm.1998.02.359. View

11.

Drake L, Scher R, Smith E, Faich G, Smith S, Hong J . Effect of onychomycosis on quality of life. J Am Acad Dermatol. 1998; 38(5 Pt 1):702-4. DOI: 10.1016/s0190-9622(98)70199-9. View

12.

Schein J, Gause D, Stier D, Lubeck D, Bates M, Fisk R . Onychomycosis. Baseline results of an observational study. J Am Podiatr Med Assoc. 1997; 87(11):512-9. DOI: 10.7547/87507315-87-11-512. View

Penetration of ((14)C)-Efinaconazole Topical Solution, 10%, Does Not Appear to Be Influenced by Nail Polish